Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model

#1867

Introduction: The development of new therapeutic strategies for cancer patients relies on the in vitro and in vivo testing of novel substances in the pre-clinical setting. So far, this has not been possible for pancreatic neuroendocrine tumors (pNET) due to lack of suitable animal models resembling the disease course in human patients.

Aim(s): The aim of the study was to establish a new animal model for pNETs.

Materials and methods: We subcutaneously transplanted tumor cells of the recetly created well-differentiated human pancreatic neuroendocrine tumor cell line NT-3 into the flanks of NOD/SCID mice.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Schrader J, Unrau L, Stahl F, Eggers C, Fahl M,

Keywords: pNET, insulinoma, SSTR,